Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3894486 | 0.77 | KDM4E (0.41) | LMNAKMT2AMEN1CA1CA12 | |
| SCHEMBL7029367 | 0.76 | TSHR (0.44) | LMNAKMT2AMEN1CA1CA12 | |
| SCHEMBL7023259 | 0.76 | LMNA (0.67) | LMNAKMT2AMEN1CA1CA12 | |
| SCHEMBL15507858 | 0.71 | LMNA (1.00) | LMNAKMT2AMEN1CA1CA12 | |
| SCHEMBL11723158 | 0.68 | ALDH1A1 (0.41) | LMNAKMT2AMEN1CA12HPGD | |
| SCHEMBL23133121 | 0.67 | LMNA (0.67) | LMNAKMT2AMEN1CA1CA12 | |
| SCHEMBL11719747 | 0.67 | MAPT (0.38) | LMNAKMT2AMEN1CA1CA12 | |
| SCHEMBL12407119 | 0.64 | LMNA (0.61) | LMNAKMT2AMEN1CA1CA12 | |
| SCHEMBL31485251 | 0.63 | HTT (0.55) | LMNAKMT2AMEN1CA12HPGD | |
| SCHEMBL10933682 | 0.62 | LMNA (0.46) | LMNAKMT2AMEN1CA1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10398680-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2019-09-03 | — | — | US | disclosed |
| US-10398749-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190240195-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | Board of Regents of the Nevada System of Higher Education, on behalf of the Univ of Nevada, Reno (US) | 2019-08-08 | — | — | US | disclosed |
| US-10272069-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2019-04-30 | — | — | US | disclosed |
| US-10206903-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2019-02-19 | — | — | US | disclosed |
| US-10028992-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2018-07-24 | — | — | US | disclosed |
| US-9980943-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEMS OF HIGHER EDUCATION ON BEHALF OF THE NEVADA, RENO (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170340606-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170224657-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-10 | — | — | US | disclosed |
| US-9707210-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2017-07-18 | — | — | US | disclosed |
| US-9566310-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2017-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10272069-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | LMNA 484/4885KMT2A 3360/4885MEN1 4859/4885 |
| US-10028992-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | LMNA 484/4885KMT2A 3360/4885MEN1 4859/4885 |
| US-10398680-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | LMNA 484/4885KMT2A 3360/4885MEN1 4859/4885 |
| US-10398749-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | LMNA 484/4885KMT2A 3360/4885MEN1 4859/4885 |
| US-20170224657-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | LMNA 484/4885KMT2A 3360/4885MEN1 4859/4885 |
| US-20190240195-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | LMNA 484/4885KMT2A 3360/4885MEN1 4859/4885 |
| US-10206903-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | LMNA 484/4885KMT2A 3360/4885MEN1 4859/4885 |
| US-20170340606-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | LMNA 484/4885KMT2A 3360/4885MEN1 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.